How long does a course of apalutamide (Ansenko) usually take and its efficacy evaluation

Apalutamide (Apalutamide) is an oral non-steroidal androgen receptor inhibitor, mainly used for patients with castration-resistant prostate cancer (nmCRPC) and some advanced prostate cancer. A standard course of treatment is usually taken orally once a day and taken continuously for 28 days as a cycle. The course of treatment can be carried out continuously according to the patient's condition and tolerance. Long-term maintenance is usually required to delay disease progression to the maximum extent.

Clinical studies have shown that apalutamide can significantly delay metastasis-free survival (MFS) in nmCRPC patients. In the SPARTAN study, the median metastasis-free survival of patients in the apalutamide group was extended to approximately 40 months, while that in the control group was only 16 months, showing a clear efficacy advantage. At the same time, the incidence of skeletal-related events in patients was reduced, and the progression of the disease was significantly slowed down.

After one or several courses of treatment, most patients can observe thatPSA (prostate-specific antigen) levels decrease or stabilize, indicating that the biological activity of the tumor is inhibited. In addition, the patient's overall quality of life was maintained well, and his energy and daily activities the next day were less affected. These efficacy feedback provide an intuitive reference for clinicians to evaluate the effectiveness of treatment courses.

Despite the remarkable efficacy, patients still need to regularly monitor liver function, blood pressure and cardiovascular indicators while taking apalutamide to prevent potential adverse reactions such as fatigue, rash or hypertension. The dosage of the treatment course can be adjusted appropriately according to individual tolerance, but it should not be interrupted at will to avoid affecting the long-term efficacy. Overall, continuous treatment with apalutamide can effectively delay disease progression and is an important long-term management solution for prostate cancer patients.

Reference materials:https://www.drugs.com/